Abstract CT076: Multicenter phase II study of nivolumab in previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma - Mayo clinic Phase 2 Consortium P2C-MN026, NCI9742, NCT02339558
Brigette Ma(Chinese University of Hong Kong), Anthony T.�C. Chan(Chinese University of Hong Kong), Sanna McKinzie(Mayo Clinic in Arizona), Mark Agulnik(Northwestern University), Edwin P. Hui(Johns Hopkins University), Boon Cher Goh(National University of Singapore), Barbara J. Gitlitz(University of Southern California), Ka‐Fai To(Chinese University of Hong Kong), Douglas R. Adkins(Washington University in St. Louis), Julie A. Kish(Moffitt Cancer Center), Kwok Wai Lo(Chinese University of Hong Kong), Brian A. Costello(Mayo Clinic in Arizona), Jonathan W. Riess(University of California Davis Medical Center), Howard Streicher(National Cancer Institute), Adam Pettinger(Johns Hopkins University), Dean Lim(Cleveland Clinic), Nathan R. Foster(University Health Network), Kevin J. Cullen(University of Maryland, Baltimore), Alex Y. Chang(Cornell University)
Cited by 2
Related Papers
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k